A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies

NCT00445198 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer
Small Cell Lung Carcinoma

Interventions

DRUG: ABT-263

Sponsor

AbbVie (prior sponsor, Abbott)

Collaborators

[object Object]